Breast Cancer, Colorectal Cancer, Gastric Cancer, Gastrointestinal Stromal Tumors, Liver Metastases, Liver Metastasis Colon Cancer, Melanoma, Periampullary Cancer, Renal Cell Cancer, Sarcoma, Squamous Cell Carcinoma
Conditions
Brief summary
The purpose of this study is to test an experimental oncolytic adenovirus called DNX-2440 in patients with resectable multifocal (≥ 2 lesions) liver metastasis, who are scheduled to have curative-intent liver resection surgery. Up to 18 patients will receive two sequential intra-tumoral injections of DNX-2440 into a metastatic liver tumor prior to surgery for liver resection, to evaluate safety and biological endpoints across 3 dose levels (dose escalation). Upon conclusion of the dose-escalation phase, the selected safe and biologically appropriate dose will be administered using the same schema for an additional 12 patients with colorectal cancer liver metastasis (expansion cohort) using established biologic endpoints.
Interventions
BIOLOGICALDNX-2440
DNX-2440 is a replication competent oncolytic adenovirus expressing human OX40 ligand.
Sponsors
H. Lee Moffitt Cancer Center and Research Institute
DNAtrix, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Male or female aged ≥ 18 years at time of consent * Diagnosis of liver metastases from colorectal, breast, gastric, periampullary, melanoma, renal cell cancer, sarcoma, squamous cell carcinoma or gastrointestinal stromal tumor * Multiple (≥ 2) liver tumors * Candidate for curative-intent surgery * Stated willingness to comply with all study procedures and availability for the duration of the study. * Candidates eligible for targeted therapy, as per standard of care guidelines (and based on mutational status as indicated), must have completed therapy * Preoperative chemotherapy is allowed Key
Exclusion criteria
* Recurrence of liver metastasis * Diagnosis of neuroendocrine tumor liver metastasis * Liver metastasis treated with \> 12 cycles of systemic chemotherapy * Condition that requires ongoing systemic immunosuppressive therapy * Evidence of inadequate organ function based on lab parameters * Liver transaminases (aspartate aminotransferase \[AST\] and/or alanine aminotransferase \[ALT\]) or total bilirubin \> 5x the upper limits of normal * Males or females who refuse to use a double-barrier form of birth control during the study and for up to 6 months after injection with DNX-2440
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum tolerated dose (MTD) achieved during dose-escalation phase | 1.5 Years | The MTD will be defined as the highest tolerated dose below the dose that results in greater than or equal to one-third of the subjects exposed who experience a dose-limiting toxicity (DLT). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of DNX-2440 assessed by Tumor Regression Grade (TRG) score | 3 Years | Efficacy in tumor cell killing will be measured using the TRG score (1-5) for the resected specimens |
| Viral replication | 3 Years | Viral replication will be assessed by quantitative measurement of viral protein expression by IHC |
| Measure Immune response with cell response panels | 3 Years | Immunotherapeutic responses will be assessed by examining features and measuring changes following the intervention for Immunologic microenvironment (T-cell and Myeloid-cell response panels-tissue). |
| Measure Immune response with ImmunoSEQsec | 3 Years | Immunotherapeutic responses will be assessed by measuring changes in T-cell receptor (TCR) repertoire - tissue and blood. |
| Measure Immune response with ELISPOT | 3 Years | Immunotherapeutic responses will be assessed by measuring T-cell response (ELISPOT - tissue/blood). |
Countries
United States
Outcome results
None listed